---
document_datetime: 2025-09-25 12:10:01
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/proquad-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: proquad-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6531937
conversion_datetime: 2025-12-24 22:00:29.019593
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ProQuad

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|------------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IA_IN / | C.I HUMAN AND VETERINARY MEDICINAL | 24/09/2025                          |                                             | SmPC and PL                      | To update sections 4.4 and 4.8 of the SmPC and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000300468                     | PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |             | section 4 of the PL to implement the signal recommendations on 'Varicella vaccine (live); measles, mumps, rubella and varicella vaccine (live) - New aspect of the known risk of encephalitis (EPITT no 20180)' adopted at the 10 July 2025 PRAC.       |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000253336 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add \"skin granuloma (associated with vaccine derived rubella virus)\" to the list of adverse drug reactions with the frequency \"not known' based on clinical trial data and post-marketing reports; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement various minor updates to the Product Information text of M-M-RvaxPro and ProQuad. In | 24/07/2025 | SmPC and PL | SmPC section 4.8 is updated to add \"skin granuloma (associated with vaccine derived rubella virus)\" to the list of adverse drug reactions with the frequency \"not known'. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | the PL is being revised.                                                                                                                                                           |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000255229 | B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished product - Accepted | 12/06/2025 | N/A |